Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Investing Activities (2024 - 2025)

Prelude Therapeutics' Cash from Investing Activities history spans 2 years, with the latest figure at -$60.3 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 372.8% year-over-year to -$60.3 million; the TTM value through Dec 2025 reached $53.5 million, down 40.73%, while the annual FY2025 figure was $53.5 million, 40.73% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$60.3 million at Prelude Therapeutics, down from $40.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $62.2 million in Q1 2025 and bottomed at -$60.3 million in Q4 2025.